Materials and methods for stratifying and treating cancers
AssigneesThe Institute of Cancer Research: Royal Cancer Hospital, The Royal Marsden NHS Foundation Trust
InventorsAlex Lee, Paul Huang, Maggie Cheang, Robin Jones
Life of this patent
Estimating the term…
Abstract
The present invention relates to materials and methods for stratifying and treating cancers and to methods of identifying/selecting patients for treatment of cancer with tyrosine kinase inhibitors. Gene expression profiles, TP53 mutations and FGFR1 and PDGFRA expression are used to identify/select/stratify the cancers and patients.
Claims32
A method of selecting an individual with cancer for treatment with a TKI, the method comprising:
- (a) determining the expression levels in a biological sample obtained from the individual of 40 or more of the genes selected from table 4, wherein said biological sample comprises cells, nucleic acids and/or proteins from cancer, and
- (b) selecting an individual for treatment with the TKI based on the expression levels of those genes.
8-33. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A kit for use in identifying a cancer suitable for treatment with a TKI, the kit comprising probes for detecting the expression levels of at least 40 at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 240, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220 or all 225 of the genes in table 4.
49-53. (canceled)
A method of determining a prognosis following TKI treatment in an individual, the method comprising determining the expression levels of 40 or more genes from table 4.
57-63. (canceled)
A method of treating cancer in an individual identified as having a cancer having the expression levels of the 40 or more genes in table 4 a closer match to a first, second, fourth or fifth reference centroid than a third reference centroids, the method comprising administering an anti-PDGFRA antibody, binding fragment thereof or a pharmaceutical composition comprising said antibody or said binding fragment to the individual, wherein the reference centroids are:
- (a) a first reference centroid corresponding to the expression profile of said 40 or more genes determined in a first group of subjects known to have cancer with PDGFRA-Hi/FGFR1-Lo expression;
- (b) a second reference centroid corresponding to the expression profile of said 40 or more genes determined in a second group of subjects known to have cancer with mutated TP53 and PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression;
- (c) a third reference centroid corresponding to the expression profile of said 40 or more genes determined in a third group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup A shown in table 3 than subgroups B or C, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression;
- (d) a fourth reference centroid corresponding to the expression profile of said 40 or more genes determined in a fourth group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup B shown in table 3 than subgroups A or C, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression;
- and
- (e) a fifth reference centroid corresponding to the expression profile of said 40 or more genes determined in a fifth group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup C shown in table 3 than subgroups A or B, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression.
66-69. (canceled)
Dependencies are inferred from the claim text.